Ambrosia has raised $5.0M in total across 2 funding rounds.
Ambrosia's investors include SOSV.
Ambrosia Systems is a San Francisco-based medical technology company developing wearable health devices, including the RIZZ smart ring, the world's first non-invasive continuous glucose monitor (CGM) that also tracks sleep, stress, heart health, activity, oxygen levels, and skin temperature.[3][4] It serves health enthusiasts, metabolic health-focused individuals, professionals, athletes, and those seeking needle-free glucose monitoring, solving the problem of invasive blood glucose tracking with affordable, multi-sensor wearables compatible across iOS and Android devices.[3][4] The company builds on prior innovations like the low-cost NightRider BluCon NFC reader for real-time CGM from Abbott's FreeStyle Libre sensors, used in over 100 countries, with strong growth in global markets including India.[3][4]
Previously focused on NFC-to-Bluetooth bridges for healthcare sensors, Ambrosia Systems has pivoted to direct consumer wearables, shipping products worldwide and positioning RIZZ as a scalable AI-driven platform for metabolic wellness and fitness recovery.[4]
Ambrosia Systems originated in San Francisco as a fast-growing medtech firm specializing in affordable NFC reading devices for health monitoring.[3][4] Key early innovation was the NightRider BluCon, which connects Abbott FreeStyle Libre sensors to phones or watches via Bluetooth, enabling continuous glucose reads every 5 minutes without native app support—5 years ahead of competitors like Dexcom for Apple Watch integration.[4] This achieved pivotal traction, becoming the first real-time CGM solution in India and other markets at under $1,000/year, with shipments to over 100 countries.[4]
The company evolved to launch RIZZ, a smart ring for non-invasive CGM targeting pre-diabetes and non-insulin T2D users, building on years of proven hardware and AI for glucose, wellness, and recovery metrics.[4] Founders and leadership details are not specified in available data, but the focus remains on easy-to-use tech for patients, providers, and consumers.[3]
Ambrosia Systems rides the explosive growth in wearable health tech and non-invasive CGM, driven by rising pre-diabetes rates, consumer demand for metabolic insights, and AI personalization in wellness.[4] Timing aligns with post-2020 telehealth boom and regulatory shifts favoring direct-to-consumer devices, amplified by Apple Health and Google Fit integrations.[3][4] Market forces like aging populations, fitness tracking ubiquity, and competition from Oura/Dexcom favor its low-cost, multi-sensor approach, influencing the ecosystem by democratizing CGM in emerging markets and accelerating needle-free innovation.[4]
Ambrosia Systems is poised to expand RIZZ globally, leveraging its hardware-AI stack for subscriptions in metabolic coaching and partnerships with insurers for T2D management.[4] Trends like AI-driven preventive health and ring form factors will propel growth, potentially challenging incumbents through affordability and non-invasive edge.[4] Its influence may evolve from niche CGM enabler to mainstream wellness leader, redefining accessible metabolic tracking much like its BluCon pioneered real-time monitoring.
Ambrosia has raised $5.0M across 2 funding rounds. Most recently, it raised $4.0M Seed in December 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2018 | $4.0M Seed | SOSV | |
| Oct 1, 2017 | $1.0M Seed | SOSV |
